Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Change from baseline in a composite self-rating of the four most troubling symptoms identified at baseline.
Change from baseline and actual values for other efficacy variables (HAM-A, PGIS, CGI-S, SDS, and Q-LES-Q; safety assessment through adverse event reports, laboratory tests, vital signs, physical examinations, and concomitant medications.
18 Years to 65 Years (Adult)
June 28, 2004
July 23, 2012
† Study has passed its completion date and status has not been verified in more than two years.